Pealkiri: 

Variability of bothersome menopausal symptoms over time - a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT)

Autorid: Hemminki E, Regushevskaya E, Luoto R, Veerus P
Väljaandja/tellija: BMC Womens Health
Märksõnad: naised, hormoonid, epidemioloogilised uuringud
Välja antud: 2012
Tüüp: Teaduslik artikkel/kogumik
Viide: Hemminki E, Regushevskaya E, Luoto R, Veerus P. Variability of bothersome menopausal symptoms over time - a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). BMC Womens Health 2012;12:44.
Link: http://www.biomedcentral.com/1472-6874/12/44
Alamvaldkonnad:Mittenakkushaigused
Kirjeldus: Background
Very little data are available on the natural course or level of disturbance of vasomotor symptoms among middle-aged women. Using readily collected trial data we studied the persistence of vasomotor symptoms among untreated women.
Methods
In a trial comparing combined hormone therapy to placebo or no treatment (control groups), a cohort of women aged 50-59 at recruitment were followed annually by questionnaires. Women in the control groups (n¿=¿486) were grouped by the number of years followed, with the prevalence and severity of symptoms calculated both cross-sectionally and longitudinally.
Results
About two thirds of the women (67%) reported vasomotor symptoms and half (46%) bothersome symptoms at recruitment. In the cross-sectional analysis, their prevalence declined between recruitment and 1-year follow-up (32% bothersome symptoms) and 2-year follow-up (27%). Thereafter it remained about the same level. In the longitudinal analysis, there was a notable variation in the prevalence of disturbing vasomotor symptoms over time, time entering the study and the compliance to the surveys. In the two groups having most follow-up times, the proportion of women with bothersome symptoms first increased and then decreased.
Conclusions
There was a notable variability in the development of disturbing vasomotor symptoms over time in a selected group of women aged 50-59. Population-based follow-up studies of untreated women would be useful to estimate the symptom burden.